Valve-in-valve (ViV) procedures have emerged from an off-label procedure to a safe and efficient alternative to redo aortic valve replacement in the treatment of symptomatic structural valve deterioration (SVD). During ViV procedures, optimal placement of the transcatheter heart valve (THV) inside the degenerated bioprosthesis is of paramount importance regarding complications such as device embolization, coronary obstruction, periprosthetic regurgitation, residual gradients, and mitral valve injury, but also for the attainment of optimal hemodynamics. In the case of the Mosaic (Medtronic, Minneapolis, MN) valve, the limited radiopaque landmarks represent a challenge to a reproducible, optimal implantation. Such implantation may require multiple contrast injections and transesophageal echocardiogram (TEE) guidance. We herein describe a computer-assisted ViV procedure inside a deteriorated Mosaic valve, achieving reproducible optimal placement using a preacquired library of bioprostheses 3D models. Our approach suggests an evolving paradigm in ViV procedures, from safe and efficient toward optimal therapy for symptomatic SVD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ccd.29395 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acurate Neo2 for valve-in-valve treatment of degenerated 3F Enable sutureless bioprosthetic valve in nonagenarian patient: a case report.
Eur Heart J Case Rep
March 2025
Invasive Cardiology-IRCCS Istituto Auxologico Italiano, San Luca Hospital, Piazzale Brescia 20, 20148 Milan, Italy.
Background: Sutureless bioprosthetic valves (SBVs) are engineered to enable a less invasive surgical valve replacement procedure in patients at high surgical risk. Valve degeneration is a relatively common occurrence across all types of surgical valves, including SBVs. Valve-in-valve (ViV) procedures are increasingly becoming the preferred treatment for many cases of valve degeneration due to their minimally invasive nature and favourable long-term outcomes.
View Article and Find Full Text PDFValve-in-Valve Transapical Transcatheter Aortic Valve Replacement with Concomitant Percutaneous Coronary Intervention: A Case Report.
Am J Case Rep
March 2025
Division of Cardiac Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
BACKGROUND Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is increasingly used, as older high-risk patient populations require repeat aortic valve replacements. The most common approach to ViV-TAVR is through a transfemoral approach or alternative vascular access sites, such as transcarotid or transsubclavian TAVR. Within this population, some patients become ineligible for ViV-TAVR due to contraindications, such as severe peripheral vascular disease, necessitating an alternative.
View Article and Find Full Text PDFTranscatheter aortic valve-in-valve implantation in failed stentless valves: a single-center experience.
J Invasive Cardiol
February 2025
Department of Cardiac Surgery Research, Lankenau Institute for Medical Research, Main Line Health, Wynnewood, Pennsylvania; Department of Cardiac Surgery, Lankenau Heart Institute, Main Line Health.
Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) offers an alternative to repeat cardiac surgery in selected patients. However, ViV-TAVI in previously implanted stentless valves is more challenging than in a stented valve. This single-center study aimed to analyze the outcomes of ViV-TAVI in stentless valves.
View Article and Find Full Text PDFTranscatheter aortic valve implantation vs. surgery for failed bioprosthesis: a meta-analysis of over 20 000 patients.
J Cardiovasc Med (Hagerstown)
March 2025
Division of Cardiac Surgery.
Objectives: Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) has gained popularity as a less invasive alternative to a redo surgical aortic valve replacement (redo-SAVR); which one is the preferred technique in these cases, however, remains a topic of debate, as the available data refer to retrospective studies with few patients or limited follow-up. The present metanalysis aimed to compare the short-term and long-term outcomes of the two techniques in the setting of a failed surgical bioprosthesis.
Methods: PubMed, MEDLINE, and Embase were searched on 10 November 2023 yielding 355 results (PROSPERO ID: CRD42023490612), of which 27 were suitable for meta-analysis.
Predictors of in-hospital early mortality following valve-in-valve transcatheter aortic valve replacement.
Cardiovasc Revasc Med
February 2025
Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, NJ, USA; Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ, USA.
Background: There is an increasing preference of utilizing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) after bioprosthetic valve failure. However, updated large-scale analysis investigating early-mortality after the patients underwent ViV TAVR is limited.
Objective: This study aimed to assess in-hospital early mortality and analyze the factors associated with in-hospital early mortality among patients who underwent ViV TAVR.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!